Femto Research Group revolutionises cancer treatment with p53Herbpatch©

The firm was lauded at the Healthcare Asia Award 2024 for introducing a groundbreaking, noninvasive cancer treatment, merging traditional Thai herbal wisdom with modern scientific research.

Thailand-based Femto Research Group Co., Ltd. garnered the Service Innovation of the Year - Thailand at the Healthcare Asia Award 2024 with the introduction of the p53Herbpatch©. This pioneering technology stands as a beacon of hope in the fight against cancer, specifically targeting the 20% of human cancers caused by infectious agents. Annually, these infections result in approximately 2 million new cancer cases and 1.5 million deaths worldwide, underscoring the urgent need for innovative treatment strategies.

The p53Herbpatch© represents a significant leap forward in cancer treatment, focusing on the activation of apoptosis to eradicate infected DNAs within human cancer genomes. This method aligns with the growing recognition of apoptosis as a crucial target for anticancer therapy, diverging from traditional treatments that often involve chemotherapy and radiation, which some patients may resist.

Central to this innovation is the utilisation of approximately fifty herbal extracts, meticulously selected for their apoptotic activity. The selection process, overseen by Dr. Preamrudee Kim, a respected Thai Traditional Doctor, is based on her extensive experience and profound understanding of herbal medicine's potential in cancer treatment. The herbal extracts are chosen according to the cancer type and the specific pathogenic agents identified within each cancer genome, ensuring a tailored approach to treatment.

The p53Herbpatch© employs a noninvasive delivery system, where the herbal mixture is immobilised on polyethylene patches for transdermal absorption. This novel approach eliminates the need for oral intake or direct medication, offering a patient-friendly alternative. The application process involves attaching the patches to the body's lymph nodes and lymphatic ducts using plastic wraps. These wraps generate far-infrared radiation, facilitating the dissolution and absorption of the herbal extracts through the skin. Once absorbed, these extracts target the affected organ or tissue, initiating the process of apoptosis.

An illustrative case of nasopharyngeal stage 4 (NPC) treatment with the p53Herbpatch© showcased the innovation's efficacy. The treatment led to a significant reduction in pathogenic DNA/Genomes within the patient’s genome, demonstrating the potential of this approach to clear cancer-causing infections. However, the research also highlighted the necessity of a germ-free environment to maximise the efficiency of the treatment, indicating areas for future improvement and research.

The p53Herbpatch’s© features align seamlessly with global health trends towards Personalized and Precision Medicine. It offers a noninvasive, side-effect-free treatment option that significantly reduces DNA/genome infections in cancer patients. This innovative approach has not only earned the Femto Research Group consecutive accolades from 2018-2023 but has also marked a revolutionary step in the diagnosis, management, and follow-up of DNA/genome infections in cancer patients.

The p53Herbpatch©, through its successful integration of traditional Thai medicine with cutting-edge scientific research, provides a promising new avenue for cancer treatment. It underscores the potential of integrating holistic and personalised treatment strategies into the healthcare continuum, potentially revolutionising the care for individuals battling cancer.

The Healthcare Asia Awards is presented by Healthcare Asia Magazine. To view the full list of winners, click here. If you want to join the 2025 awards programme and be acclaimed for your organisation's remarkable initiatives and contributions to the healthcare industry, please contact Julie Anne Nuñez at [email protected].